Arun K Sharma

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6070807/publications.pdf

Version: 2024-02-01

88	3,062	136950	189892
papers	citations	32 h-index	50 g-index

88	88	88	3791
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selenium Compounds, Apoptosis and Other Types of Cell Death: An Overview for Cancer Therapy. International Journal of Molecular Sciences, 2012, 13, 9649-9672.	4.1	215
2	Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents. Journal of Medicinal Chemistry, 2016, 59, 1946-1959.	6.4	122
3	Targeting Mitogen-Activated Protein Kinase/Extracellular Signalâ€“Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases. Cancer Research, 2006, 66, 8200-8209.	0.9	108
4	Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases. Drug Metabolism and Disposition, 2007, 35, 2006-2014.	3.3	95
5	Synthesis and Anticancer Activity Comparison of Phenylalkyl Isoselenocyanates with Corresponding Naturally Occurring and Synthetic Isothiocyanates. Journal of Medicinal Chemistry, 2008, 51, 7820-7826.	6.4	92
6	Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clinical Cancer Research, 2009, 15, 1674-1685.	7.0	92
7	Importance of Sphingosine Kinase (SphK) as a Target in Developing Cancer Therapeutics and Recent Developments in the Synthesis of Novel SphK Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 5509-5524.	6.4	88
8	Development and Therapeutic Potential of Selenazo Compounds. Journal of Medicinal Chemistry, 2020, 63, 1473-1489.	6.4	86
9	Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites. Cancer Research, 2009, 69, 1892-1900.	0.9	70
10	Development of a Selective Modulator of Aryl Hydrocarbon (Ah) Receptor Activity that Exhibits Anti-Inflammatory Properties. Chemical Research in Toxicology, 2010, 23, 955-966.	3.3	66
11	Peroxisome proliferator-activated receptor-Î²/Î´ (PPARÎ²/Î´) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis, 2007, 28, 2641-2649.	2.8	65
12	Peroxisome proliferator-activated receptor-Î²/Î´ (PPARÎ²/Î´) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology, 2008, 243, 236-243.	4.2	63
13	Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7498-7502.	2.2	57
14	Ligand Activation of Peroxisome Proliferator-Activated Receptor-Î²/Î´ Inhibits Cell Proliferation in Human HaCaT Keratinocytes. Molecular Pharmacology, 2008, 74, 1429-1442.	2.3	55
15	Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway. Bioorganic and Medicinal Chemistry, 2011, 19, 6006-6014.	3.0	53
16	Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation. Drug Metabolism and Disposition, 2007, 35, 1942-1948.	3.3	51
17	Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-Î²/Î´ Antagonist GSK3787. Molecular Pharmacology, 2010, 78, 419-430.	2.3	51
18	Synthesis and biological evaluation of some 2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-arylethanones: Antibacterial, DNA photocleavage, and anticancer activities. European Journal of Medicinal Chemistry, 2014, 81, 267-276.	5.5	49

#	Article	IF	Citations
19	Melanoma Chemoprevention in Skin Reconstructs and Mouse Xenografts Using Isoselenocyanate-4. Cancer Prevention Research, 2011, 4, 248-258.	1.5	46
20	Suppression of Cytokine-Mediated Complement Factor Gene Expression through Selective Activation of the Ah Receptor with 3â€²,4â€²-Dimethoxy-Î±-naphthoflavone. Molecular Pharmacology, 2011, 79, 508-519.	2.3	46
21	Mutagenesis and carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: a potential new model for oral cancer. International Journal of Cancer, 2012, 130, 2783-2790.	5.1	46
22	The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model. Clinical Cancer Research, 2011, 17, 4474-4483.	7.0	42
23	Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile. International Journal of Nanomedicine, 2016, Volume 11, 3607-3619.	6.7	42
24	Novel seleno- and thio-urea derivatives with potent inÂvitro activities against several cancer cell lines. European Journal of Medicinal Chemistry, 2016, 113, 134-144.	5.5	41
25	The Apoptotic Mechanism of Action of the Sphingosine Kinase 1 Selective Inhibitor SKI-178 in Human Acute Myeloid Leukemia Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 494-508.	2.5	40
26	Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity. European Journal of Medicinal Chemistry, 2016, 123, 407-418.	5.5	40
27	A ConvenientTransDiastereoselective Synthesis of 3-Butadienylazetidinones and Their Dielsâ^'Alder Cycloaddition Reactions. Journal of Organic Chemistry, 1996, 61, 5506-5509.	3.2	38
28	Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Experimental Hematology, 2014, 42, 883-896.	0.4	37
29	Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells. PLoS ONE, 2013, 8, e78570.	2.5	37
30	In vitro growth inhibition of human cancer cells by novel honokiol analogs. Bioorganic and Medicinal Chemistry, 2012, 20, 3202-3211.	3.0	36
31	Mechanisms of oral carcinogenesis induced by dibenzo[a,l]pyrene: An environmental pollutant and a tobacco smoke constituent. International Journal of Cancer, 2013, 133, 1300-1309.	5.1	36
32	Identification and Quantification of DNA Adducts in the Oral Tissues of Mice Treated with the Environmental Carcinogen Dibenzo[a,l]pyrene by HPLC-MS/MS. Chemical Research in Toxicology, 2011, 24, 1297-1303.	3.3	34
33	Post SELECT: selenium on trial. Future Medicinal Chemistry, 2013, 5, 163-174.	2.3	34
34	Preliminary physiologically based pharmacokinetic models for benzo[a]pyrene and dibenzo[def,p]chrysene in rodents. Toxicology and Applied Pharmacology, 2011, 257, 365-376.	2.8	33
35	Novel selenadiazole derivatives as selective antitumor and radical scavenging agents. European Journal of Medicinal Chemistry, 2018, 157, 14-27.	5.5	32
36	Reactions of 1,3-diaza-1,3-butadienes with haloketenes - rearrangements accompanying [4+2] cycloaddition reactions.. Tetrahedron, 1994, 50, 7579-7588.	1.9	31

#	Article	IF	Citations
37	Effect of artificial mixtures of environmental polycyclic aromatic hydrocarbons present in coal tar, urban dust, and diesel exhaust particulates on MCF-7 cells in culture. Environmental and Molecular Mutagenesis, 2004, 44, 99-107.	2.2	31
38	Microwave-Assisted Suzuki Cross-Coupling Reaction, a Key Step in the Synthesis of Polycyclic Aromatic Hydrocarbons and Their Metabolites. Journal of Organic Chemistry, 2007, 72, 8987-8989.	3.2	31
39	Synthesis and biological evaluation of novel spiro 6-methoxytetralin-1,3â€²-pyrrolidine based organoselenocyanates against cadmium-induced oxidative and hepatic damage in mice. European Journal of Medicinal Chemistry, 2010, 45, 3265-3273.	5.5	31
40	Synthesis and [4+2] cycloaddition reactions of 4-(N-allyl-N-aryl)amino-1,3-diaza-1,3-butadienes with vinyl-, isopropenyl- and chloroketenes: Entry to novel pyrimidinone/fused pyrimidinone derivatives. Tetrahedron, 1997, 53, 13841-13854.	1.9	29
41	Development of novel naphthalimide derivatives and their evaluation as potential melanoma therapeutics. European Journal of Medicinal Chemistry, 2011, 46, 3331-3338.	5.5	29
42	Development of Isoselenocyanate Compoundsâ€™ Syntheses and Biological Applications. Journal of Medicinal Chemistry, 2019, 62, 5261-5275.	6.4	29
43	Effect of ligand activation of peroxisome proliferator-activated receptor-Î²/Î´ (PPARÎ²/Î´) in human lung cancer cell lines. Toxicology, 2008, 254, 112-117.	4.2	28
44	Phenylalkyl isoselenocyanates vs phenylalkyl isothiocyanates: Thiol reactivity and its implications. Chemico-Biological Interactions, 2012, 200, 28-37.	4.0	27
45	Rational Incorporation of Selenium into Temozolomide Elicits Superior Antitumor Activity Associated with Both Apoptotic and Autophagic Cell Death. PLoS ONE, 2012, 7, e35104.	2.5	27
46	The chemopreventive effect of withaferin A on spontaneous and inflammation-associated colon carcinogenesis models. Carcinogenesis, 2018, 39, 1537-1547.	2.8	27
47	NSAIDs: Old Acquaintance in the Pipeline for Cancer Treatment and Preventionâ”€Structural Modulation, Mechanisms of Action, and Bright Future. Journal of Medicinal Chemistry, 2021, 64, 16380-16421.	6.4	25
48	Synthesis and regioselective [4+2] cycloaddition/nucleophilic reactions of N-arylamino-1:3-diaza-1:3-butadienes with ketenes and accompanying rearrangements. Tetrahedron, 1995, 51, 7459-7468.	1.9	23
49	Regioselective [4+2] cycloaddition versus nucleophilic reactions of N-arylamino substituted 1,3-diaza-1,3-butadienes with ketenes: Synthesis of pyrimidinone and fused pyrimidinone derivatives. Part II. Tetrahedron, 1997, 53, 13829-13840.	1.9	23
50	Synthesis and bioactivity of sphingosine kinase inhibitors and their novel aspirinyl conjugated analogs. European Journal of Medicinal Chemistry, 2010, 45, 4149-4156.	5.5	23
51	Impact of Pregnancy on the Pharmacokinetics of Dibenzo[def,p]chrysene in Mice. Toxicological Sciences, 2013, 135, 48-62.	3.1	22
52	Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells. European Journal of Medicinal Chemistry, 2018, 143, 1919-1930.	5.5	21
53	Comparative Tumorigenicity of the Environmental Pollutant 6-Nitrochrysene and Its Metabolites in the Rat Mammary Gland. Chemical Research in Toxicology, 2002, 15, 972-978.	3.3	20
54	Ligand activation of peroxisome proliferator-activated receptor-Î²/Î´ (PPARÎ²/Î´) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Letters, 2010, 288, 219-225.	7.2	20

#	Article	IF	Citations
55	Phenylbutyl Isoselenocyanate Modulates Phase I and II Enzymes and Inhibits 4-(Methylnitrosamino)-1-(3-Pyridyl)- 1-Butanoneâ€“Induced DNA Adducts in Mice. Cancer Prevention Research, 2011, 4, 1884-1894.	1.5	20
56	Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents. European Journal of Medicinal Chemistry, 2014, 86, 211-218.	5.5	20
57	Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Expert Opinion on Therapeutic Patents, 2011, 21, 807-812.	5.0	19
58	Identification and quantification of six-ring C26H16 cata-condensed polycyclic aromatic hydrocarbons in a complex mixture of polycyclic aromatic hydrocarbons from coal tar. Analytical and Bioanalytical Chemistry, 2015, 407, 9165-9176.	3.7	19
59	Synthesis, in Vitro Metabolism, Cell Transformation, Mutagenicity, and DNA Adduction of Dibenzo[c,mno]chrysene. Chemical Research in Toxicology, 2002, 15, 964-971.	3.3	18
60	Simultaneous Detection of Deoxyadenosine and Deoxyguanosine Adducts in the Tongue and Other Oral Tissues of Mice Treated with Dibenzo[a,l]pyrene. Chemical Research in Toxicology, 2014, 27, 1199-1206.	3.3	18
61	Synthesis of 5-dienyl pyrimidinones and tandem [1,5] shifts in [4+2] cycloadditions of 1,3-diazabuta-1,3-dienes with butadienylketene. Tetrahedron Letters, 1998, 39, 7205-7208.	1.4	17
62	Design, synthesis, and anti-breast cancer evaluation of new triarylethylene analogs bearing short alkyl- and polar amino-/amido-ethyl chains. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1963-1969.	2.2	17
63	Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIÎ± and Akt pathway inhibitor, and evaluation of its anti-melanoma activity. European Journal of Medicinal Chemistry, 2017, 135, 282-295.	5.5	17
64	Synthesis of isosteric selenium analog of the PPARÎ²/Î´ agonist GW501516 and comparison of biological activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4050-4052.	2.2	16
65	Interaction between APC and Fen1 during breast carcinogenesis. DNA Repair, 2016, 41, 54-62.	2.8	16
66	Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile. Journal of Antibiotics, 2018, 71, 713-721.	2.0	15
67	Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer. Genes and Cancer, 2017, 8, 713-724.	1.9	15
68	Regioselective and unusual [3+2] cycloadditions of Î±-nitrosostyrenes with 1,3-diaza-1,3-butadienes. Tetrahedron Letters, 1993, 34, 7961-7964.	1.4	14
69	Characterization of Dibenzo[a,l]pyrene-trans-11,12-diol (Dibenzo[def,p]chrysene) Glucuronidation by UDP-Glucuronosyltransferases. Chemical Research in Toxicology, 2011, 24, 1549-1559.	3.3	14
70	Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53â€mediated apoptosis in LNCaP prostate cancer cells. Molecular Carcinogenesis, 2018, 57, 1055-1066.	2.7	13
71	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. European Journal of Medicinal Chemistry, 2019, 161, 456-467.	5.5	13
72	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. Oncotarget, 2017, 8, 57246-57264.	1.8	13

#	Article	IF	Citations
73	Convenient Syntheses of Dibenzo[c,p]chrysene and Its Possible Proximate and Ultimate Carcinogens:Â In Vitro Metabolism and DNA Adduction Studies. Journal of Organic Chemistry, 2005, 70, 4962-4970.	3.2	12
74	Investigation of the genotoxicity of dibenzo[c,p]chrysene in human carcinoma MCF-7 cells in culture. Chemico-Biological Interactions, 2006, 164, 181-191.	4.0	12
75	The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer. PLoS ONE, 2013, 8, e59380.	2.5	12
76	Recent Advances in the Chemistry and Therapeutic Evaluation of Naturally Occurring and Synthetic Withanolides. Molecules, 2022, 27, 886.	3.8	12
77	Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic. International Journal of Molecular Sciences, 2019, 20, 521.	4.1	11
78	Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-Î²B Signaling, and Synergizes with Gemcitabine Cytotoxicity. International Journal of Molecular Sciences, 2021, 22, 4966.	4.1	11
79			